Johanna Tulkki - Senzime AB COO CTO

All Insiders Sweden . 
Stock . Senzime AB . Stakeholders . Insider . Johanna Tulkki
SEZI Stock  SEK 5.70  0.06  1.04%   

Insider

Johanna Tulkki is COO CTO of Senzime AB
Age 53
Phone46 18 51 56 40
Webhttps://senzime.com

Senzime AB Management Efficiency

The company has return on total asset (ROA) of (0.2949) % which means that it has lost $0.2949 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6434) %, meaning that it generated substantial loss on money invested by shareholders. Senzime AB's management efficiency ratios could be used to measure how well Senzime AB manages its routine affairs as well as how well it operates its assets and liabilities.
Senzime AB has accumulated 617 K in total debt. Senzime AB has a current ratio of 3.7, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Senzime AB until it has trouble settling it off, either with new capital or with free cash flow. So, Senzime AB's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Senzime AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Senzime to invest in growth at high rates of return. When we think about Senzime AB's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Aishat BislievaBoule Diagnostics AB
N/A
Karen BornsteinBoule Diagnostics AB
N/A
Veronica WallinEpisurf Medical AB
37
Maria EdebrinkXbrane Biopharma AB
54
Fredrik ZetterbergEpisurf Medical AB
48
Samuel WagnerXbrane Biopharma AB
N/A
Kerstin HasselgrenXSpray Pharma AB
62
Lars LevinC Rad AB
52
Grald JessonXSpray Pharma AB
N/A
Tim ThurnC Rad AB
42
Mattias IsakssonBoule Diagnostics AB
N/A
Priscilla KazumbaC Rad AB
N/A
Christina HagerstrandXSpray Pharma AB
46
Christina HugossonBoule Diagnostics AB
60
Emelie GozziC Rad AB
N/A
Thomas WalzXSpray Pharma AB
63
AnnaKarin EkbergXSpray Pharma AB
57
Anette LindqvistXbrane Biopharma AB
57
Ivan AstralagaC Rad AB
N/A
Xiaodong WangC Rad AB
44
Stephen CaswellEpisurf Medical AB
42
Senzime AB develops patient-oriented monitoring systems that assess patients biochemical and physiological processes before, during and after surgery in Sweden. Senzime AB was founded in 1997 and is based in Uppsala, Sweden. Senzime AB is traded on Stockholm Stock Exchange in Sweden. Senzime AB (SEZI) is traded on Stockholm Exchange in Sweden and employs 18 people.

Management Performance

Return On Equity-0.64
Return On Asset-0.29

Senzime AB Leadership Team

Elected by the shareholders, the Senzime AB's board of directors comprises two types of representatives: Senzime AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Senzime. The board's role is to monitor Senzime AB's management team and ensure that shareholders' interests are well served. Senzime AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Senzime AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
Anders Selin, VP Sales
Johanna Tulkki, COO CTO
Rianne Waninge, Application Scientist
Pia Renaudin, Chief Officer
Anders Jacobson, Chief Technical Officer
Catrin Molund, Business Development Director
Slavoljub Grujicic, Chief Officer

Senzime Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Senzime AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.64
Return On Asset-0.29
Operating Margin(8.35) %
Current Valuation771.13 M
Shares Outstanding69.88 M
Shares Owned By Insiders43.52 %
Shares Owned By Institutions17.18 %
Price To Earning(25.28) X
Price To Book2.70 X
Price To Sales60.95 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Senzime Stock Analysis

When running Senzime AB's price analysis, check to measure Senzime AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Senzime AB is operating at the current time. Most of Senzime AB's value examination focuses on studying past and present price action to predict the probability of Senzime AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Senzime AB's price. Additionally, you may evaluate how the addition of Senzime AB to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY